Scoop: No­var­tis’ re­treat on CAR-T in­cludes ax­ing most of its se­nior ex­ecs on the team

Us­man “Oz” Azam

No­var­tis’ plan to pull back on CAR-T in­cludes purg­ing most of the se­nior ex­ecs in­volved in the project, sig­nal­ing the phar­ma gi­ant’s R&D re­treat is more ex­ten­sive than the com­pa­ny has want­ed to ad­mit so far.

End­points News, which broke the sto­ry on No­var­tis’ sur­pris­ing R&D move, ini­tial­ly ob­tained the top frag­ment of an in­ter­nal cor­po­rate memo au­thored by Us­man “Oz” Azam at No­var­tis spelling out that the com­pa­ny is dis­solv­ing its cell and gene ther­a­py unit re­spon­si­ble for its pi­o­neer­ing work on CAR-T. Now we have the rest of it, and it in­cludes this on the team ex­ecs:

Un­for­tu­nate­ly a num­ber of col­leagues will be im­pact­ed by this change as many po­si­tions are be­ing elim­i­nat­ed. Im­pact­ed US-based as­so­ciates are be­ing no­ti­fied in meet­ings to­day. As­so­ci­ates based in Basel will learn more about their in­di­vid­ual cir­cum­stances on Thurs­day. The ma­jor­i­ty of the CG­TU Lead­er­ship Team mem­bers, who are among the best I have worked with, are al­so im­pact­ed.

Ear­li­er in the week, No­var­tis por­trayed the de­ci­sion to in­te­grate the unit in­to its on­col­o­gy di­vi­sion as an ef­fi­cien­cy move, some­thing No­var­tis does on a reg­u­lar ba­sis. The com­pa­ny, a spokesper­son not­ed, would con­tin­ue to work in the field and “with a new in­te­grat­ed de­vel­op­ment mod­el, we can ef­fi­cient­ly ad­vance our work on CART as part of our fo­cus in im­muno-on­col­o­gy by rein­te­grat­ing the func­tions.”

Elim­i­nat­ing the ex­ec­u­tive team un­der­scores con­cerns that No­var­tis, one of the three key lead­ers in CAR-T, along with Kite and Juno, is step­ping away just as the first CAR-T ther­a­pies are near­ing ap­proval. And No­var­tis has said that it will con­tin­ue to push its lead pro­gram CTL019 in pe­di­atric r/r ALL to the FDA in ear­ly 2017 and the EMA lat­er in 2017.

Just two years ago, in a Forbes cov­er sto­ry, No­var­tis CEO Joe Jimenez vowed to pur­sue CAR-T with a no-ex­pens­es-spared ap­proach to cur­ing can­cer. But how se­ri­ous can it be about CAR-T when the se­nior team lead­ers are be­ing axed as part of a move to elim­i­nate 120 jobs out of the 400 af­fect­ed?

I asked No­var­tis rep­re­sen­ta­tives that ques­tion ear­ly Fri­day, but have yet to hear back. (Up­date: Here’s their re­sponse.)

Azam goes on at one point to as­sure the 400-mem­ber group, many of whom were about to be axed, that “We have led the in­dus­try in trans­form­ing the prac­tice of med­i­cine with CART ther­a­py…the clin­i­cal and reg­u­la­to­ry teams will move to Glob­al Drug De­vel­op­ment and specif­i­cal­ly On­col­o­gy Glob­al De­vel­op­ment, and our col­leagues who are sup­port­ing com­mer­cial readi­ness will move to the On­col­o­gy or­ga­ni­za­tion.”

Here is the en­tire memo ob­tained by End­points:

Dear Col­leagues,

I still vivid­ly re­mem­ber the mo­ment that David Ep­stein in­vit­ed me to lead a new Unit ded­i­cat­ed to Cell & Gene Ther­a­pies. It was a mix­ture of ex­cite­ment and fear – a feel­ing that fu­els my en­tre­pre­neur­ial spir­it, and one that so many of you share. The risk of em­bark­ing on a new ad­ven­ture in un­chart­ed ter­ri­to­ry is that things don’t al­ways work out how you en­vi­sioned. To­day, I have the un­for­tu­nate task of an­nounc­ing that we are dis­solv­ing the Cell & Gene Ther­a­pies Unit. The ad­ven­ture start­ed years ago with the ini­ti­a­tion of the Penn col­lab­o­ra­tion. Af­ter rec­og­niz­ing the unique­ness of this ther­a­py, the or­ga­ni­za­tion im­ple­ment­ed our CG­TU de­sign struc­ture to bring to­geth­er bright minds in dis­parate func­tions from across No­var­tis to act as a SWAT team and fig­ure out how to make this a suc­cess. And we did. In the space of two years we com­plet­ed an un­prece­dent­ed tech trans­fer of CAR tech­nol­o­gy to a com­mer­cial-grade, GMP qual­i­ty, scal­able man­u­fac­tur­ing site in Mor­ris Plains, gained clar­i­ty on the in­di­ca­tions with the great­est ben­e­fit/risk pro­file, ini­ti­at­ed and ful­ly en­rolled two glob­al mul­ti-site clin­i­cal tri­als in two dif­fer­ent in­di­ca­tions, and laid the ground­work for the evo­lu­tion of fu­ture cell pro­cess­ing. But most im­por­tant­ly, as Kathy says, we saved the lives of sev­er­al kinder­garten class­es and dozens of par­ents and grand­par­ents.

We have led the in­dus­try in trans­form­ing the prac­tice of med­i­cine with CART ther­a­py.

While we were fo­cused on cell and gene ther­a­pies, the larg­er No­var­tis or­ga­ni­za­tion con­tin­ued to evolve. We el­e­vat­ed the role of On­col­o­gy, we have in­te­grat­ed our glob­al de­vel­op­ment func­tion, and we are op­er­at­ing, more than ever, as one No­var­tis. This is the time to re-in­te­grate the Unit back to the func­tions. We have grown, the or­ga­ni­za­tion has grown, and it’s time to come back to­geth­er. An in­te­grat­ed Mor­ris Plains foot­print in­clud­ing Tech Ops, Qual­i­ty and IT process de­vel­op­ment will move un­der BT­DM, the clin­i­cal and reg­u­la­to­ry teams will move to Glob­al Drug De­vel­op­ment and specif­i­cal­ly On­col­o­gy Glob­al De­vel­op­ment, and our col­leagues who are sup­port­ing com­mer­cial readi­ness will move to the On­col­o­gy or­ga­ni­za­tion.

Un­for­tu­nate­ly a num­ber of col­leagues will be im­pact­ed by this change as many po­si­tions are be­ing elim­i­nat­ed. Im­pact­ed US-based as­so­ciates are be­ing no­ti­fied in meet­ings to­day. As­so­ci­ates based in Basel will learn more about their in­di­vid­ual cir­cum­stances on Thurs­day. The ma­jor­i­ty of the CG­TU Lead­er­ship Team mem­bers, who are among the best I have worked with, are al­so im­pact­ed.

I know this news may be dif­fi­cult, and I know you have ques­tions. I would like to elab­o­rate on what I have shared here in a Town Hall this af­ter­noon at 15:00 CET/3:00 PM EDT. I know this is short no­tice, so we have arranged many ways for you to con­nect from mul­ti­ple time zones. We have booked rooms in East Hanover, Mor­ris Plains (where I will be) and Cam­bridge, or you can di­al in via We­b­cast or tele­con­fer­ence if you would like to hear more. A meet­ing in­vi­ta­tion will fol­low.

The DCT-OS: A Tech­nol­o­gy-first Op­er­at­ing Sys­tem - En­abling Clin­i­cal Tri­als

As technology-enabled clinical research becomes the new normal, an integrated decentralized clinical trial operating system can ensure quality, deliver consistency and improve the patient experience.

The increasing availability of COVID-19 vaccines has many of us looking forward to a time when everyday things return to a state of normal. Schools and teachers are returning to classrooms, offices and small businesses are reopening, and there’s a palpable sense of optimism that the often-awkward adjustments we’ve all made personally and professionally in the last year are behind us, never to return. In the world of clinical research, however, some pandemic-necessitated adjustments are proving to be more than emergency stopgap measures to ensure trial continuity — and numerous decentralized clinical trial (DCT) tools and methodologies employed within the last year are likely here to stay as part of biopharma’s new normal.

Onno van de Stolpe, Galapagos CEO (Thierry Roge/Belga Mag/AFP via Getty Images)

Gala­pa­gos chops in­to their pipeline, drop­ping core fields and re­or­ga­niz­ing R&D as the BD team hunts for some­thing 'trans­for­ma­tive'

Just 5 months after Gilead gutted its rich partnership with Galapagos following a bitter setback at the FDA, the Belgian biotech is hunkering down and chopping the pipeline in an effort to conserve cash while their BD team pursues a mission to find a “transformative” deal for the company.

The filgotinib disaster didn’t warrant a mention as Galapagos laid out its Darwinian restructuring plans. Forced to make choices, the company is ditching its IPF molecule ’1205, while moving ahead with a Phase II IPF study for its chitinase inhibitor ’4617.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Ron DePinho (file photo)

A 'fly­over' biotech launch­es in Texas with four Ron De­Pin­ho-found­ed com­pa­nies un­der its belt

In his 13 years at Genzyme, Michael Wyzga noticed something about East Coast drugmakers. Execs would often jet from Boston or New York to San Francisco to find more assets, and completely miss the work being done in flyover states, like Texas or Wisconsin.

“If it doesn’t come out of MGH or MIT or Harvard, probably not that interesting,” he said of the mindset.

Now, he and some well-known industry players are looking to change that, and they’ve reeled in just over $38 million to do it.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Stéphane Bancel, Getty

Mod­er­na CEO brush­es off US sup­port for IP waiv­er, eyes more than $19B in Covid-19 vac­cine sales in 2021

Moderna is definitively more concerned with keeping pace with Pfizer in the race to vaccinate the world against Covid-19 than it is with Wednesday’s decision from the Biden administration to back an intellectual property waiver that aims to increase vaccine supplies worldwide.

In its first quarter earnings call on Thursday, Moderna CEO Stéphane Bancel shrugged off any suggestion that the newly US-backed intellectual property waiver would impact his company’s vaccine or bottom line. Still, the company’s stock price fell by about 9% in early morning trading.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Ad­comm splits slight­ly in fa­vor of FDA ap­prov­ing Chemo­Cen­tryx’s rare dis­ease drug

The FDA’s Arthritis Advisory Committee on Thursday voted 10 for and 8 against the approval of ChemoCentryx’s $CCXI investigational drug avacopan as a treatment for adults with a rare and serious disease known as anti-neutrophil cytoplasmic autoantibody (ANCA)-vasculitis.

The vote on whether the FDA should approve the drug was preceded by a split vote of 9 to 9 on whether the efficacy data support approval, and 10 to 8 that the safety profile of avacopan is adequate enough to support approval.

Paul Hastings, Nkarta CEO

With no up­front pay­ment or mile­stones on the line, Nkar­ta and CRISPR join forces on CAR-NK search

Most deals in biotech come with hefty upfront payments attached, and the promise of big biobucks if a program works out. Not this one.

Nkarta has struck what CEO Paul Hastings calls a “real collaboration” with CRISPR Therapeutics to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T program. The duo will split all R&D costs — and any worldwide profits — 50/50, Hastings said.

Brent Saunders (Richard Drew, AP Images)

OcuWho? Star deal­mak­er turned aes­thet­ics czar Brent Saun­ders flips back in­to biotech. But who’s he team­ing up with now?

Brent Saunders went on a tear of headline-blazing deals building Allergan, merging and rearranging a variety of big companies into one before an M&A pact with Pfizer blew up and sent him on a bout of biotech drug deals. That didn’t work so well, so under pressure, he got his buyout at AbbVie — which needed a big franchise like Botox. And it was no big surprise to see him riding the SPAC wave into a recent $1 billion-plus deal that left him in the executive chairman’s seat at an aesthetics outfit — now redubbed The Beauty Health Company — holding a big chunk of the equity.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Drug pric­ing watch­dog joins the cho­rus of crit­ics on Bio­gen's ad­u­canum­ab: What about charg­ing $2,560 per year?

As if Biogen’s aducanumab isn’t controversial enough, the researchers at drug pricing watchdog ICER have drawn up the contours of a new debate: If the therapy does get approved for Alzheimer’s by June, what price should it command?

Their answer: At most $8,290 per year — and perhaps as little as $2,560.

Even at the top of the range, the proposed price is a fraction of the $50,000 that Wall Street has reportedly come to expect (although RBC analyst Brian Abrahams puts the consensus figure at $11.5K). With critics, including experts on the FDA’s advisory committee, making their fierce opposition to aducanumab’s approval loud and clear, the pricing pressure adds one extra wrinkle Biogen CEO Michel Vounatsos doesn’t need as he orders full-steam preparation for a launch.

'Chang­ing the whole game of drug dis­cov­ery': Leg­endary R&D vet Roger Perl­mut­ter leaps back in­to work as a biotech CEO

Roger Perlmutter needs no introduction to anyone remotely involved in biopharma. As the R&D chief first at Amgen and then Merck, he’s built a stellar reputation and a prolific career steering new drugs toward the market for everything from cancer to infectious diseases.

But for years, he’s also held a less known title: science partner at The Column Group, where he’s regularly consulted about the various ideas the VCs had for new startups.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.